DEBIOPHARM
Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, announced today their participation in the 2024 World AMR conference from September 5th-6th in Philadelphia, Pennsylvania, USA. For the last decade, Debiopharm has been committed to developing new antimicrobials for patients by conducting research on a novel class of antibiotics that target hard-to-treat infections, caused by WHO priority pathogens. Now in its third year of sponsoring World AMR, Debiopharm is proud to support the conference’s mission to unite key decision-makers in AMR from international government bodies, policy organizations, and the healthcare sector to meet, discuss, and formulate initiatives to tackle the emerging threat of AMR effectively.
This year, Debiopharm’s Head of Global Value & Access, Jennifer Quinn, will present within the Impact, Policy and Awareness Track and lead a roundtable discussion on how to move the needle on fair reimbursement for antibiotics. Focused on actionable ways to leverage current reimbursement models, Jennifer’s presentation will outline a tangible framework for payer negotiations and discuss evidence needs for products that will reach the market before ‘pull incentives’ become available.
“We’re looking forward to open discussions and networking opportunities with public organizations and other infectious disease industry experts to put into place practical solutions to combat the reimbursement challenged that help to fuel AMR.” – Jennifer Quinn, Head of Global Value & Access.
World AMR 2023 Session details |
Congress agenda |
Speaker |
Presentation Sept. 5th 11:20AM EST
|
How can current reimbursement models be leveraged while waiting for 'pull incentives'? |
Jennifer Quinn, Head of Global Value & Access |
Roundtable discussion Sept. 5th 01:30PM EST
|
What data is needed to fit current payer evidence requirements and how can we generate it? |
Jennifer Quinn, Head of Global Value & Access |
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor, selectively targeting Staphylococcus’ essential bacterial fatty acid biosynthesis pathway. Afabicin is active against Staphylococcus spp., of which methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or intravenously. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a global Phase 2 trial in bone and joint infections is being conducted, comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first-in-class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 has been developed as an oral drug with activity against. Neisseria gonorrhoeae, the bacteria causing the sexually transmitted disease gonorrhea. Untreated gonorrhea can cause serious and permanent health issues including infertility, ectopic pregnancy, long-term pelvic/abdominal pain, blindness in newborns and in rare cases also have a lethal outcome.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci. As a result of high selectivity, FabI inhibitors specifically target selected pathogens, and potentially preserve intestinal microbiota. Debiopharm’s FabI inhibitors meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on X. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
Sources
- Antimicrobial Resistance Collaborators. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827078184/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Signs Strategic Collaboration Agreement With AWS to Accelerate Financial Services Industry Transformation With AI and Core Modernization25.11.2025 11:30:00 CET | Press release
HCLTech, a leading global technology company, today announced that it has signed a strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in the financial services industry through autonomous, AI-powered solutions. The collaboration brings together HCLTech’s deep domain expertise and AWS to deliver transformative outcomes for financial services organizations. “We understand that a digital journey is of strategic importance and the need of the hour is for a trusted partner that can engage across the transformation lifecycle,” said Srinivasan Seshadri, Chief Growth Officer and Global Head of Financial Services at HCLTech. “Financial institutions face increasing pressure to modernize their systems, deliver exceptional customer experiences, and meet sustainability requirements and many struggle with legacy infrastructure, siloed data, and complex regulatory requirements. Our collaboration with AWS addresses these challenges by providing proven solutions a
Bridgepoint to Partner With ht.digital, the Leading Digital Asset Transparency Layer25.11.2025 09:00:00 CET | Press release
Bridgepoint to become majority shareholder in ht.digital, a London headquartered specialist provider of audit, accounting, assurance, operational and technology solutions to the digital asset ecosystem ht.digital has delivered organic revenue growth of c.100% over the last two years, scaling rapidly in a fast-growing market The partnership will accelerate ht.digital’s international expansion and continued investment in technology, talent and brand Bridgepoint, one of the world’s leading mid-market investors, today announced that it has agreed to acquire a majority stake in ht.digital, a leading, London-headquartered provider of digital asset assurance and technology solutions. The investment will be made by Bridgepoint Development Capital V – Bridgepoint’s lower middle-market fund focused on supporting fast-growing businesses across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251125907148/en/ Digital assets – incl
Thredd Signs Landmark Agreement to Enable Visa Cloud Connect Globally25.11.2025 09:00:00 CET | Press release
Agreement sets stage for strengthened global reach, scalability, and resilience for fintechs and banks worldwide Thredd, a leading next-generation global payments processor, today announced that it has signed an agreement to enable Visa Cloud Connect on a global scale. This milestone reflects Thredd’s continued investment in cloud-first infrastructure and reinforces its role as a global technology leader in payments processing. Visa Cloud Connect allows organisations to access VisaNet, Visa’s secure and powerful global payments network, through their own cloud-based infrastructure. Purpose-built for cloud-native clients, Visa Cloud Connect can help deliver increased flexibility, faster time to market, and seamless scalability across borders. Under the agreement, Thredd will connect across three global Visa Cloud Connect endpoints, committing to a full global rollout. Once live, this will eliminate the need for multiple regional integrations, helping our clients gain new geographies and
Allvue Expands European Footprint, Names KPMG Luxembourg as Core Implementation Partner25.11.2025 08:56:00 CET | Press release
The partnership offers managers seamless access to specialized local expertise and regulatory knowledge, ensuring accelerated confidence in adopting world-class, API-first technology, including Allvue’s AI tool, Andi. Allvue Systems, LLC (“Allvue”), a leading software technology provider for the private capital markets, today announced an expansion of its current presence in EMEA, naming KPMG Luxembourg as its core implementation partner for all client deliverables for Europe. The strategic collaboration is designed to meet the growing demand from global asset managers leveraging Luxembourg as the premier European fund domicile. By aligning Allvue’s world-class, unified technology platform and solutions with KPMG’s renowned local expertise in private assets, deep regional relationships, and plurilingual delivery capabilities, the partnership offers clients a faster, more effective path to technology adoption. “Our mission is to make private markets more transparent, efficient, and conn
Datassential Expands Global Menu Intelligence with Debut of Global Launches25.11.2025 08:30:00 CET | Press release
Datassential, the leading global food and beverage intelligence platform, announced the debut of Global Launches, an expanded menu–tracking solution offering a unified view of new menu items and limited-time offers (LTOs) across major international markets. Global Launches now tracks menu innovation across hundreds of restaurant chains in the European, Latin American, and Asia-Pacific markets. Building on the robust menu tracking already available in the U.S. and Canada, this expansion gives foodservice businesses a comprehensive view of new menu items and LTOs around the globe, providing unmatched visibility into how trends and flavors appear across worldwide markets and evolve to fit local tastes. “Innovation doesn’t happen in one market at a time — it’s global, constant, and increasingly fast,” said Jim Emling, CEO of Datassential. “Global Launches now offers our customers a single, trusted source to see what’s launching across the world, how concepts are localized, and where the ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom